Trials / Completed
CompletedNCT02164045
Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529
Study to Evaluate the Effect of Food on the Pharmacokinetics of BMS-626529 From an Extended-Release Formulation of BMS-663068 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 38 (actual)
- Sponsor
- ViiV Healthcare · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
The current food effect study is being performed to support a Phase 3 study with BMS 663068. Results from this study will inform whether patients in the upcoming Phase 3 study can be given the flexibility to dose BMS-663068 in the fasted state, if so desired.
Detailed description
Primary Purpose: Other: To assess the effect of food on the steady-state exposure of BMS-626529 when administered as BMS 663068 600 mg twice daily (BID) to healthy subjects Acquired Immune Deficiency Syndrome (AIDS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-663068 | BMS-663068 |
Timeline
- Start date
- 2014-06-24
- Primary completion
- 2014-07-25
- Completion
- 2014-07-25
- First posted
- 2014-06-16
- Last updated
- 2017-07-27
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02164045. Inclusion in this directory is not an endorsement.